KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Non-Current Deferred Tax Liability (2018 - 2025)

Takeda Pharmaceutical (TAK) has 5 years of Non-Current Deferred Tax Liability data on record, last reported at $767.7 million in Q1 2024.

  • For Q1 2024, Non-Current Deferred Tax Liability fell 62.47% year-over-year to $767.7 million; the TTM value through Mar 2024 reached $767.7 million, down 62.47%, while the annual FY2024 figure was $788.9 million, 60.62% down from the prior year.
  • Non-Current Deferred Tax Liability reached $767.7 million in Q1 2024 per TAK's latest filing, down from $2.0 billion in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $5.1 billion in Q1 2021 and bottomed at $767.7 million in Q1 2024.
  • Average Non-Current Deferred Tax Liability over 4 years is $3.0 billion, with a median of $3.0 billion recorded in 2022.
  • Peak YoY movement for Non-Current Deferred Tax Liability: fell 24.24% in 2022, then tumbled 62.47% in 2024.
  • A 4-year view of Non-Current Deferred Tax Liability shows it stood at $5.1 billion in 2021, then dropped by 24.24% to $3.9 billion in 2022, then crashed by 47.34% to $2.0 billion in 2023, then tumbled by 62.47% to $767.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $767.7 million in Q1 2024, $2.0 billion in Q1 2023, and $3.9 billion in Q1 2022.